| scholarly article | Q13442814 |
| P50 | author | Jaime H Vera | Q42237581 |
| P2093 | author name string | David Back | |
| George Scullard | |||
| Alan Winston | |||
| Saye Khoo | |||
| Adam Croucher | |||
| Laura J Else | |||
| Borja Mora-Peris | |||
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies | Q34139859 | ||
| Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients | Q34141845 | ||
| Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state | Q34510726 | ||
| Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients | Q34606683 | ||
| Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
| Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. | Q34932654 | ||
| Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. | Q35875096 | ||
| Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study | Q36247045 | ||
| Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration | Q36266689 | ||
| Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). | Q36447469 | ||
| Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers | Q36558240 | ||
| Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. | Q37291454 | ||
| Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 | ||
| Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. | Q37968986 | ||
| Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial | Q38980584 | ||
| Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds | Q43081850 | ||
| The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients | Q43102292 | ||
| Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). | Q43296433 | ||
| Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study | Q43572711 | ||
| Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. | Q53569230 | ||
| The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. | Q54571477 | ||
| British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 | Q57180881 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| ritonavir | Q422618 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 1348-1353 | |
| P577 | publication date | 2013-01-30 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects | |
| P478 | volume | 68 |
| Q47894419 | CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study |
| Q34360012 | CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers |
| Q30366071 | Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications |
| Q42226571 | Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. |
| Q36868170 | Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment |
| Q34400849 | Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study |
Search more.